Synopsis
Synopsis
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol Hydrochloride
2. Fingolimod
3. Fty 720
4. Fty-720
5. Fty720
6. Gilenia
7. Gilenya
1. 162359-56-0
2. Fty720
3. Fingolimod Hcl
4. Gilenia
5. Gilenya
6. Fty 720
7. Fty-720
8. Fingolimod (hydrochloride)
9. Fingolimod (fty720) Hcl
10. 2-amino-2-(4-octylphenethyl)propane-1,3-diol Hydrochloride
11. Fingolimod, Hcl
12. Fty720 Hydrochloride
13. Fingolimod Hydrochloride [usan]
14. 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol Hydrochloride
15. Fty720 Free Base
16. Chebi:63112
17. Fingolimod Hydrochlorid
18. 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol;hydrochloride
19. Fingolimod (as Hydrochloride)
20. Fty-720 Hydrochloride
21. 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol Hydrochloride
22. G926ec510t
23. Mfcd00939512
24. 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol Hydrochloride
25. Gilenya (tn)
26. 1,3-propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-, Hydrochloride
27. 1,3-propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, Hydrochloride
28. 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol, Hydrochloride
29. Fty-720a
30. Fingolimod (fty720)
31. Imusera
32. Unii-g926ec510t
33. 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol Hydrochloride
34. Fty720,fingolimod
35. Fingolimodhydrochloride
36. Fin;limod Hydrochloride
37. Fty720 - Fingolimod
38. Fingolimod Hclfty-720
39. Epitope Id:156573
40. Schembl81362
41. Mls006010179
42. Chembl544665
43. Fingolimod Hydrochloride- Bio-x
44. Dtxsid00167364
45. Ex-a960
46. Tdi-132
47. Bcpp000225
48. Bcp01808
49. 2-amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol Hcl
50. Fingolimod Hydrochloride (jan/usan)
51. Fingolimod Hydrochloride [mi]
52. S5002
53. Fingolimod Hydrochloride [jan]
54. Akos005145784
55. Ac-1929
56. Am84549
57. Bcp9000705
58. Ccg-265016
59. Cs-0114
60. Ks-1172
61. Fingolimod Hydrochloride [usp-rs]
62. Fingolimod Hydrochloride [who-dd]
63. Bf164458
64. Hy-12005
65. Smr004701287
66. Sy057854
67. Db-014816
68. A8548
69. F1018
70. Ft-0643569
71. Sw219384-1
72. Ec-000.2314
73. Fingolimod Hydrochloride [orange Book]
74. A25158
75. D04187
76. Fingolimod Hydrochloride [ep Monograph]
77. Fingolimod Hydrochloride [usp Monograph]
78. 359f560
79. Sr-01000942237
80. Q-101363
81. Sr-01000942237-2
82. Q27132395
83. 2-(4-octylphenethyl)-2-aminopropane-1,3-diol Hydrochloride
84. 2-amino-2-[2-(4-octylphenyl) Ethyl]-1,3-propanediol Hydrochloride
85. 2-amino-2-[2-(4-octylphenyl)-ethyl]-1,3-propanediol Hydrochloride
86. [1-hydroxy-2-(hydroxymethyl)-4-(4-octylphenyl)butan-2-yl]azanium;chloride
87. 2-amino-2-[2-(4-n-octylphenyl)ethyl]propane-1,3-diol Hydrochloride
88. 2-amino-2-[2-(4-octyl-phenyl)-ethyl]-propane -1,3-diol Hydrochloride
89. 2-amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol Hydrochloride
90. 1,3-propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, Hydrochloride (1:1)
Molecular Weight | 343.9 g/mol |
---|---|
Molecular Formula | C19H34ClNO2 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 12 |
Exact Mass | 343.2278070 g/mol |
Monoisotopic Mass | 343.2278070 g/mol |
Topological Polar Surface Area | 66.5 Ų |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 258 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Gilenya |
PubMed Health | Fingolimod (By mouth) |
Drug Classes | Immune Modulator |
Drug Label | Fingolimod is a sphingosine 1-phosphate receptor modulator.Chemically, fingolimod is 2-amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol hydrochloride. Its structure is shown below: Fingolimod hydrochloride is a white to practically white powder that i... |
Active Ingredient | Fingolimod |
Dosage Form | Capsule |
Route | Oral |
Strength | 0.5mg |
Market Status | Prescription |
Company | Novartis |
2 of 2 | |
---|---|
Drug Name | Gilenya |
PubMed Health | Fingolimod (By mouth) |
Drug Classes | Immune Modulator |
Drug Label | Fingolimod is a sphingosine 1-phosphate receptor modulator.Chemically, fingolimod is 2-amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol hydrochloride. Its structure is shown below: Fingolimod hydrochloride is a white to practically white powder that i... |
Active Ingredient | Fingolimod |
Dosage Form | Capsule |
Route | Oral |
Strength | 0.5mg |
Market Status | Prescription |
Company | Novartis |
Gilenya is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:
- Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 and 5. 1).
or
- Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.
Sphingosine 1 Phosphate Receptor Modulators
Agents that affect the function of G-protein coupled SPHINGOSINE 1-PHOSPHATE RECEPTORS. Their binding to the receptors blocks lymphocyte migration and are often used as IMMUNOSUPPRESSANTS. (See all compounds classified as Sphingosine 1 Phosphate Receptor Modulators.)
Immunosuppressive Agents
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)
L04AA27
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A gilenya manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of gilenya, including repackagers and relabelers. The FDA regulates gilenya manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. gilenya API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of gilenya manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A gilenya supplier is an individual or a company that provides gilenya active pharmaceutical ingredient (API) or gilenya finished formulations upon request. The gilenya suppliers may include gilenya API manufacturers, exporters, distributors and traders.
click here to find a list of gilenya suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A gilenya DMF (Drug Master File) is a document detailing the whole manufacturing process of gilenya active pharmaceutical ingredient (API) in detail. Different forms of gilenya DMFs exist exist since differing nations have different regulations, such as gilenya USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A gilenya DMF submitted to regulatory agencies in the US is known as a USDMF. gilenya USDMF includes data on gilenya's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The gilenya USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of gilenya suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The gilenya Drug Master File in Japan (gilenya JDMF) empowers gilenya API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the gilenya JDMF during the approval evaluation for pharmaceutical products. At the time of gilenya JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of gilenya suppliers with JDMF on PharmaCompass.
A gilenya CEP of the European Pharmacopoeia monograph is often referred to as a gilenya Certificate of Suitability (COS). The purpose of a gilenya CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of gilenya EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of gilenya to their clients by showing that a gilenya CEP has been issued for it. The manufacturer submits a gilenya CEP (COS) as part of the market authorization procedure, and it takes on the role of a gilenya CEP holder for the record. Additionally, the data presented in the gilenya CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the gilenya DMF.
A gilenya CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. gilenya CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of gilenya suppliers with CEP (COS) on PharmaCompass.
A gilenya written confirmation (gilenya WC) is an official document issued by a regulatory agency to a gilenya manufacturer, verifying that the manufacturing facility of a gilenya active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting gilenya APIs or gilenya finished pharmaceutical products to another nation, regulatory agencies frequently require a gilenya WC (written confirmation) as part of the regulatory process.
click here to find a list of gilenya suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing gilenya as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for gilenya API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture gilenya as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain gilenya and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a gilenya NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of gilenya suppliers with NDC on PharmaCompass.
gilenya Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of gilenya GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right gilenya GMP manufacturer or gilenya GMP API supplier for your needs.
A gilenya CoA (Certificate of Analysis) is a formal document that attests to gilenya's compliance with gilenya specifications and serves as a tool for batch-level quality control.
gilenya CoA mostly includes findings from lab analyses of a specific batch. For each gilenya CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
gilenya may be tested according to a variety of international standards, such as European Pharmacopoeia (gilenya EP), gilenya JP (Japanese Pharmacopeia) and the US Pharmacopoeia (gilenya USP).
LOOKING FOR A SUPPLIER?